Adaptive Biotechnologies Corporation (NASDAQ:ADPT) on Monday announced plans to separate its Minimal Residual Disease (MRD) and Immune Medicine businesses.
• Adaptive Biotechnologies stock is trending lower. Why are ADPT shares declining?
Adaptive Separation Plan Could Sharpen Focus On MRD Business
William Blair, in an investor note on Tuesday, agreed with the assessment and said the move the firm believes could simplify the company’s investment story and create greater strategic flexibility for its Minimal Residual Disease (MRD) franchise.
Analyst Andrew Brackmann said investors will likely seek more clarity on the future of the Immune Medicine segment, with management expected to identify its preferred path by the end of the year.
“Regardless, we like this move as it simplifies the thesis and adds flexibility, particularly for the MRD franchise,” Brackmann wrote.
William Blair maintained its Outperform rating on the stock.
Analyst Sees Limited Downside From Immune Medicine Separation
According to the firm, the separation of Immune Medicine appears at least neutral to Adaptive’s valuation, noting that the segment likely contributed little or even negative value within investor valuation models.
In a downside scenario where Adaptive is unable to find a buyer and a spin-off proves impractical, the company would still benefit by eliminating the segment’s expected cash burn of $15 million to $20 million this year and separating those results from its core financial performance.
MRD Franchise Could Become Clearer Investment Story
The analyst argued that Immune Medicine had complicated the investment case for MRD by creating a financial drag that investors had to account for, despite the segment not being a significant contributor to valuation.
With that overhang potentially removed, William Blair believes the MRD business may receive greater attention as it continues to post volume growth exceeding 35% and expand margins.
Concurrently, on Wednesday, the company priced its $300 million 0% convertible senior notes due 2031 to repay the OrbiMed agreement and simplify its capital structure.
In its press release, the company also said that it would use the remaining proceeds for opportunistic initiatives in the MRD business.
ADPT Stock Price Activity: Adaptive Biotechnologies shares were down 1.60% at $16.94 at the time of publication on Wednesday, according to Benzinga Pro data.
Image via Shutterstock
